Physician profile
Michael K Kuo
NPI 1427057686
$3,331.30
in general payments reported to CMS, 2019-2025
31 companies · $172 in 2025
The $172 reported for 2025 was less than what a typical Pain Medicine (Physical Medicine & Rehabilitation) provider received nationally (typical 2025 total: $400).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $613 · 2021: $686 · 2022: $498 · 2023: $492 · 2024: $337 · 2025: $172.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,001.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $695.29 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $427.13 | 2019-2025 | Relistor |
| Scilex Pharmaceuticals INC. | $380.31 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $370.32 | 2019-2024 | Xtampza, Belbuca |
| Lilly USA, LLC | $177.48 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $150.99 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $127.48 | 2020-2021 | |
| Pfizer INC. | $120.84 | 2019-2021 | |
| Ibsa Pharma INC. | $92.54 | 2021-2024 | Licart, Tirosint, Tirosint |
| Zyla Life Sciences, INC. | $89.81 | 2019-2020 | |
| Boston Scientific Corporation | $82.69 | 2019-2025 | General - Therapies |
| Ferring Pharmaceuticals INC. | $71.23 | 2019-2023 | Euflexxa |
| Biohaven Pharmaceutical Holding Company LTD. | $60.76 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $58.07 | 2020 | |
| Amgen INC. | $52.71 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $41.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $34.96 | 2022-2023 | Seglentis |
| Depuy Synthes Sales INC. | $34.33 | 2023-2025 | Monovisc, Orthovisc, Peak |
| Pacira Therapeutics, INC. | $30.85 | 2021 | |
| Arbor Pharmaceuticals, INC. | $24.58 | 2021 | |
| Fidia Pharma USA INC. | $23.38 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.74 | 2023 | Strensiq |
| Vertex Pharmaceuticals Incorporated | $21.74 | 2025 | |
| Novartis Pharmaceuticals Corporation | $21.68 | 2019 | |
| Bioventus LLC | $19.40 | 2019 | |
| Grt US Holding, INC. | $19.15 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.85 | 2019 | |
| Hikma Pharmaceuticals USA | $16.89 | 2021 | |
| Allergan, INC. | $16.73 | 2020 | |
| Averitas Pharma INC. | $15.74 | 2023 | Qutenza |
| Abbott Laboratories | $13.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Kuo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.